吉非替尼治疗非小细胞肺癌的研究进展

吉非替尼是一种新型的分子靶向抗癌药物，它选择性抑制表皮生长因子受体酪氨酸激酶而发挥作用。大规模临床研究显示，吉非替尼对于晚期非小细胞肺癌具有明显的抗肿瘤活性，并能较快改善患者的临床症状，提高晚期生活质量。与传统化疗药物相比，吉非替尼具有瞄准特定的分子靶点、不良反应小和特异性强等优点。2003年5月，美国FDA通过快速审批程序，批准吉非替尼应用于临床。目前它主要用于终末期非小细胞肺癌的二线和三线治疗。

Progress in therapy of gefitinib for Non-small cell lung cancer

Gefitinib (Iressa, ZD1839), a specific tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), is a novel molecular-targeting antineoplastic agent. In addition to its meaningful antitumor activity, gefitinib also provides improvements in quality of life and lung cancer-related symptoms in a large numbers of clinical studies. Gefitinib has a more favorable tolerability profile and less adverse effect than traditional chemotherapy agents in the treatment of tumor since it aim directly at tumour cells. On May 5, 2003, gefitinib was rapidly approval to use in clinics by the Food and Drug Administration (FDA) of United States as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Now it is mainly used as second-line or third-line therapy for NSCLC in many countries.